Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2
Crossref DOI link: https://doi.org/10.1007/s00405-015-3604-y
Published Online: 2015-03-21
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Farschtschi, Said
Kollmann, Philipp
Dalchow, Carsten
Stein, Alexander
Mautner, Victor-Felix
Text and Data Mining valid from 2015-03-21